70 related articles for article (PubMed ID: 29236307)
1. The role of proinflammatory cytokines and CXC chemokines (CXCL1-CXCL16) in the progression of prostate cancer: insights on their therapeutic management.
Ullah A; Jiao W; Shen B
Cell Mol Biol Lett; 2024 May; 29(1):73. PubMed ID: 38745115
[TBL] [Abstract][Full Text] [Related]
2. Type II Interleukin-4 Receptor Activation in Basal Breast Cancer Cells Promotes Tumor Progression via Metabolic and Epigenetic Modulation.
Williams D; Hargrove-Wiley E; Bindeman W; Valent D; Miranda AX; Beckstead J; Fingleton B
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731867
[TBL] [Abstract][Full Text] [Related]
3. The Molecular Biology of Prostate Cancer Stem Cells: From the Past to the Future.
Zhou Y; Li T; Jia M; Dai R; Wang R
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108647
[TBL] [Abstract][Full Text] [Related]
4. Distinct Expression of Surface and Genetic Biomarkers in Prostate Cancer Cell Lines.
Su CY; Huang GC; Chen IC; Chen PY; Chen YJ; Fang HW
In Vivo; 2023; 37(1):242-246. PubMed ID: 36593027
[TBL] [Abstract][Full Text] [Related]
5. Tumor promoting roles of IL-10, TGF-β, IL-4, and IL-35: Its implications in cancer immunotherapy.
Mirlekar B
SAGE Open Med; 2022; 10():20503121211069012. PubMed ID: 35096390
[TBL] [Abstract][Full Text] [Related]
6. IL-4 Counteracts the Cytotoxic Effects of Peripheral Blood Mononuclear Cells on Hormone-sensitive Prostate Cancer Cells.
Erb HHH; Culig Z; Stope MB
In Vivo; 2021; 35(4):1973-1977. PubMed ID: 34182471
[TBL] [Abstract][Full Text] [Related]
7. Involvement of IL-4, IL-13 and Their Receptors in Pancreatic Cancer.
Shi J; Song X; Traub B; Luxenhofer M; Kornmann M
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804263
[TBL] [Abstract][Full Text] [Related]
8. CD44 as a tumor biomarker and therapeutic target.
Xu H; Niu M; Yuan X; Wu K; Liu A
Exp Hematol Oncol; 2020 Dec; 9(1):36. PubMed ID: 33303029
[TBL] [Abstract][Full Text] [Related]
9. PIM protein kinases regulate the level of the long noncoding RNA H19 to control stem cell gene transcription and modulate tumor growth.
Singh N; Padi SKR; Bearss JJ; Pandey R; Okumura K; Beltran H; Song JH; Kraft AS; Olive V
Mol Oncol; 2020 May; 14(5):974-990. PubMed ID: 32146726
[TBL] [Abstract][Full Text] [Related]
10. Cancer stem cells in esophageal squamous cell cancer.
Wu Q; Wu Z; Bao C; Li W; He H; Sun Y; Chen Z; Zhang H; Ning Z
Oncol Lett; 2019 Nov; 18(5):5022-5032. PubMed ID: 31612013
[TBL] [Abstract][Full Text] [Related]
11. Epithelial-To-Mesenchymal Transition Markers and CD44 Isoforms Are Differently Expressed in 2D and 3D Cell Cultures of Prostate Cancer Cells.
Fontana F; Raimondi M; Marzagalli M; Sommariva M; Limonta P; Gagliano N
Cells; 2019 Feb; 8(2):. PubMed ID: 30754655
[TBL] [Abstract][Full Text] [Related]
12. Cancer stem-like cells enriched with CD29 and CD44 markers exhibit molecular characteristics with epithelial-mesenchymal transition in squamous cell carcinoma.
Geng S; Guo Y; Wang Q; Li L; Wang J
Arch Dermatol Res; 2013 Jan; 305(1):35-47. PubMed ID: 22740085
[TBL] [Abstract][Full Text] [Related]
13. PC3 prostate tumor-initiating cells with molecular profile FAM65Bhigh/MFI2low/LEF1low increase tumor angiogenesis.
Zhang K; Waxman DJ
Mol Cancer; 2010 Dec; 9():319. PubMed ID: 21190562
[TBL] [Abstract][Full Text] [Related]
14. Characterization of CD44 intracellular domain interaction with RUNX2 in PC3 human prostate cancer cells.
Senbanjo LT; AlJohani H; Majumdar S; Chellaiah MA
Cell Commun Signal; 2019 Jul; 17(1):80. PubMed ID: 31331331
[TBL] [Abstract][Full Text] [Related]
15. Implication of expression of Nanog in prostate cancer cells and their stem cells.
Gong C; Liao H; Guo F; Qin L; Qi J
J Huazhong Univ Sci Technolog Med Sci; 2012 Apr; 32(2):242-246. PubMed ID: 22528228
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-4 induces a CD44
Erb HHH; Guggenberger F; Santer FR; Culig Z
J Cell Biochem; 2018 May; 119(5):4103-4112. PubMed ID: 29236307
[TBL] [Abstract][Full Text] [Related]
17. The stem cell inhibitor salinomycin decreases colony formation potential and tumor-initiating population in docetaxel-sensitive and docetaxel-resistant prostate cancer cells.
Gruber M; Handle F; Culig Z
Prostate; 2020 Feb; 80(3):267-273. PubMed ID: 31834633
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
